Perspective Therapeutics, Inc. Stock: price and insider trades · United States

Every trade that managers of Perspective Therapeutics, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Health Care sector. Between 23 October 2025 and 23 October 2026, 4 insiders published 8 filings.

Purchases and sales both appear in the filings: 2 purchases (2 insiders, €36k) and 6 sales (2 insiders, €1.2M). Sales outweigh purchases by €1.1M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Biggest ticket of the year: €453k, sold by Lantheus Alpha Therapy, LLC and made public on 8 September 2026 (0.17% of market cap). Among those who bought: 1 finance chief and 1 senior executive.

Within a 30-day window, 1 purchase overlapped with buying by a second insider. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The most recent open-market purchase was published on 17 November 2025, 341 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.

For context, the typical company on the same exchange (median of 2,023 companies) published 41 filings over the same period, against 8 filings here. Looking back to 2016, when coverage begins, insiders filed 133 purchases and 6 sales.

Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and EssilorLuxottica. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.